Lantheus Shareholders Overwhelmingly Approve $8B Curium Acquisition
LNTH sits 99% above its 52-week low of $50.155.
Summary
Lantheus shareholders approved the $8 billion acquisition by Curium US at a special meeting on October 14, 2026, with 97% of votes cast in favor of the merger agreement.
Key Events · M&A and Partnerships · LNTH
-
Merger Agreement Approved
Shareholders approved the Curium US acquisition with 55,457,863 votes for, 1,563,807 against, and 162,833 abstentions — approximately 97% of votes cast in favor.
-
Advisory Compensation Proposal Passed
The non-binding advisory vote on executive compensation tied to the merger passed with 49,098,355 votes for, 7,849,138 against, and 237,009 abstentions.
-
Deal Terms Confirmed
The all-cash deal values Lantheus at up to $8.0 billion, with shareholders receiving $102.50 per share in cash plus contingent value rights worth up to $12 per share.
-
Next Milestone: Closing
With shareholder approval secured, the transaction now proceeds to closing, subject to remaining regulatory conditions and other customary closing conditions.
Analysis · LNTH · Life Sciences
The $8 billion all-cash acquisition by Curium US cleared its final shareholder hurdle, with 55.5 million shares voting in favor of the merger agreement — roughly 97% of votes cast. The advisory compensation proposal also passed, removing the last major uncertainty for shareholders, who will receive $102.50 per share in cash plus contingent value rights worth up to $12 per share. With the merger agreement approved, the transaction now moves to closing, subject to remaining regulatory conditions.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.6% of the 951 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $100.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $50.16 to $111.86. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.